Related references
Note: Only part of the references are listed.The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a real-world study: the Royal Marsden Hospital experience
Priya Sriskandarajah et al.
LEUKEMIA & LYMPHOMA (2017)
Abnormal heavy/light chain ratio after treatment is associated with shorter survival in patients with IgA myeloma
Yasuhito Suehara et al.
CANCER SCIENCE (2017)
Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist
Shahzad Raza et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2017)
Pooled analysis of the reports of pomalidomide after failure of lenalidomide and (or) bortezomib for multiple myeloma
Zhixin Sheng et al.
HEMATOLOGICAL ONCOLOGY (2016)
Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group
J. Laubach et al.
LEUKEMIA (2016)
Immunoglobulin D Multiple Myelorna: Disease Profile, Therapeutic Response, and Survival
Guo-rong Wang et al.
ACTA HAEMATOLOGICA (2016)
Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma
G. Fouquet et al.
ANNALS OF ONCOLOGY (2016)
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma
Meletios A. Dimopoulos et al.
BLOOD (2016)
Clonal Evolution in Multiple Myeloma
Bita Fakhri et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2016)
Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs
Takumi Ito et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2016)
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial et al.
LANCET (2016)
Epithelial ovarian cancer inherent resistance: May the pleiotropic interaction between reduced immunosurveillance and drug-resistant cells play a key role?
Antonio Simone Lagana et al.
GYNECOLOGIC ONCOLOGY REPORTS (2016)
A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial
Tatsuo Ichinohe et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2016)
Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results
Xavier Leleu et al.
BLOOD (2015)
Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma
Kosei Matsue et al.
CANCER SCIENCE (2015)
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
Meletios A. Dimopoulos et al.
HAEMATOLOGICA (2015)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The European Medicines Agency Review of Pomalidomide in Combination With Low-Dose Dexamethasone for the Treatment of Adult Patients With Multiple Myeloma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use
Zahra Hanaizi et al.
ONCOLOGIST (2015)
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
Meletios A. Dimopoulos et al.
HAEMATOLOGICA (2015)
Bone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood
Anna M. Aalbers et al.
HAEMATOLOGICA (2015)
Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma
Tsutomu Kobayashi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2015)
Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN
Anita K. Gandhi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents
Junya Kuroda et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2014)
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02
Xavier Leleu et al.
BLOOD (2013)
Investigation of the freely available easy-to-use software 'EZR' for medical statistics
Y. Kanda
BONE MARROW TRANSPLANTATION (2013)
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Jesus San Miguel et al.
LANCET ONCOLOGY (2013)
Practical management of adverse events in multiple myeloma: Can therapy be attenuated in older patients?
Antonio Palumbo et al.
BLOOD REVIEWS (2011)
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
A. Palumbo et al.
LEUKEMIA (2008)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
International staging system for multiple myeloma
PR Greipp et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
